医学交流课件：中国慢性气道疾病--现在与未来.ppt

Figure 3-A: The red dashed line indicated inner airway diameter of 2mm. This figure shows that the inner diameter of never-smokers was greater than 2mm as distal to the 9th generation bronchi. *: the among-group differences were statistically significant. Figure 3-B shows a similar trend of changes with Figure 3-A. The Ai7 of stage Ⅱ COPD was smaller than that of stage Ⅰ COPD (P=0.017) but greater than that of stage Ⅲ-Ⅳ COPD (P=0.003). However, Ai differed significantly between stage Ⅱ COPD and stage Ⅲ-Ⅳ COPD except for Ai8 (P=0.101) and Ai9 (P=0.115) (*). In Figure 3-C, label # indicates no significant difference between SNL and COPD patients, and among various stages of COPD (all P0.05). SNL presented with greater airway wall thickness than never-smokers in the 7th, 8th, and 9th generation bronchi (all P0.001). Figure 3-D: ** no differences between stage Ⅰ and stage Ⅱ COPD in Aw% at the 7th (P=0.300), 8th (P=0.983), and 9th generation bronchi (P=0.796). However, there were significant differences in Aw% among all the other groups (all P0.001). * Differences in Aw% of the 3rd to 6th, the 7th to 9th, and the 3rd to 9thgeneration bronchi, among COPD patients, SNL and never-smokers * 3组分组的规则如前，取正常人Aw%7~9的上限0.3作为判断阳性的标准，取2,3组患者做ROC曲线，如上图。可见MMEF，Fres的相关性最好。 * According to COPD 2007, COPD treatment has the goal as above. Most patients see doctors aiming to relieve symptoms, which can be achieved in short term by pharmacological therapy. Beyond this, based on the nature of COPD, the long term success via medication should be “impacting clinical course” and then prevent disease progression. But up to now, there is no existing medications proven to be able to slow the lung-function decline ( embodied by FEV1 decline rate) that is the hallmark of COPD. 我们前期研究显示：3/4慢阻肺患者为GOLD 1-2级患者，其人群患病率2.0% 和3.8%，总计5.8%，如果算上0级，那就更多了，当然，0级可能包含了一些非COPD病人。因此如果对这一部分病人采取干预措施，防治其进展到3-4级，对减少COPD发病和死亡可能会有非常重要的意义。 * However, the response of FEV1 and FVC were different in COPD, this differen